Business Intelligence
Go beyond the numbers to analytics-driven insights using artificial intelligence, machine learning and healthcare expertise.
-
Americas
-
Asia & Oceania
-
A-I
J-Z
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
Regions
-
Americas
-
Asia & Oceania
-
Europe
-
Middle East & Africa
-
Americas
-
Asia & Oceania
-
Europe
Europe
- Adriatic
- Belgium
- Bulgaria
- Czech Republic
- Deutschland
- España
- France
- Greece
- Hungary
- Ireland
- Israel
- Italia
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more -
Middle East & Africa
EMEA Thought Leadership
Developing IQVIA’s positions on key trends in the pharma and life sciences industries, with a focus on EMEA.
Learn more
SOLUTIONS
-
Research & Development
-
Real World Evidence
-
Commercialization
-
Safety & Regulatory Compliance
-
Technologies
LIFE SCIENCE SEGMENTS
HEALTHCARE SEGMENTS
- Information Partner Services
- Financial Institutions
- Global Public Health
- Government
- Patient Associations
- Payers
- Providers
THERAPEUTIC AREAS
- Cardiovascular
- Cell and Gene Therapy
- Central Nervous System
- GI & Hepatology
- Infectious Diseases and Vaccines
- Oncology
- Pediatrics
- Rare Diseases
- View All
Impacting People's Lives
"We strive to help improve outcomes and create a healthier, more sustainable world for people everywhere.
LEARN MORE
Harness the power to transform clinical development
Reimagine clinical development by intelligently connecting data, technology, and analytics to optimize your trials. The result? Faster decision making and reduced risk so you can deliver life-changing therapies faster.
Research & Development OverviewResearch & Development Quick Links
Real World Evidence. Real Confidence. Real Results.
Generate and disseminate evidence that answers crucial clinical, regulatory and commercial questions, enabling you to drive smarter decisions and meet your stakeholder needs with confidence.
REAL WORLD EVIDENCE OVERVIEWReal World Evidence Quick Links
See markets more clearly. Opportunities more often.
Elevate commercial models with precision and speed using AI-driven analytics and technology that illuminate hidden insights in data.
COMMERCIALIZATION OVERVIEWCommercialization Quick Links
Service driven. Tech-enabled. Integrated compliance.
Orchestrate your success across the complete compliance lifecycle with best-in-class services and solutions for safety, regulatory, quality and medical information.
COMPLIANCE OVERVIEWSafety & Regulatory Compliance Quick Links
Intelligence that transforms life sciences end-to-end.
When your destination is a healthier world, making intelligent connections between data, technology, and services is your roadmap.
TECHNOLOGIES OVERVIEWTechnology Quick Links
CLINICAL PRODUCTS
COMMERCIAL PRODUCTS
COMPLIANCE, SAFETY, REG PRODUCTS
BLOGS, WHITE PAPERS & CASE STUDIES
Explore our library of insights, thought leadership, and the latest topics & trends in healthcare.
DISCOVER INSIGHTSTHE IQVIA INSTITUTE
An in-depth exploration of the global healthcare ecosystem with timely research, insightful analysis, and scientific expertise.
SEE LATEST REPORTSFEATURED INNOVATIONS
-
IQVIA Connected Intelligence™
-
IQVIA Healthcare-grade AI™
-
-
Human Data Science Cloud
-
IQVIA Innovation Hub
-
Decentralized Trials
-
Patient Experience Solutions with Apple devices
WHO WE ARE
- Our Story
- Our Impact
- Commitment to Public Health
- Code of Conduct
- Sustainability
- Privacy
- Executive Team
NEWS & RESOURCES
Unlock your potential to drive healthcare forward
By making intelligent connections between your needs, our capabilities, and the healthcare ecosystem, we can help you be more agile, accelerate results, and improve patient outcomes.
LEARN MORE
IQVIA AI is Healthcare-grade AI
Building on a rich history of developing AI for healthcare, IQVIA AI connects the right data, technology, and expertise to address the unique needs of healthcare. It's what we call Healthcare-grade AI.
LEARN MORE
Your healthcare data deserves more than just a cloud.
The IQVIA Human Data Science Cloud is our unique capability designed to enable healthcare-grade analytics, tools, and data management solutions to deliver fit-for-purpose global data at scale.
LEARN MORE
Innovations make an impact when bold ideas meet powerful partnerships
The IQVIA Innovation Hub connects start-ups with the extensive IQVIA network of assets, resources, clients, and partners. Together, we can help lead the future of healthcare with the extensive IQVIA network of assets, resources, clients, and partners.
LEARN MORE
Proven, faster DCT solutions
IQVIA Decentralized Trials deliver purpose-built clinical services and technologies that engage the right patients wherever they are. Our hybrid and fully virtual solutions have been used more than any others.
LEARN MORE
IQVIA Patient Experience Solutions with Apple devices
Empowering patients to personalize their healthcare and connecting them to caregivers has the potential to change the care delivery paradigm.
LEARN MOREWORKING AT IQVIA
Our mission is to accelerate innovation for a healthier world. Together, we can solve customer challenges and improve patient lives.
LEARN MORELIFE AT IQVIA
Careers, culture and everything in between. Find out what’s going on right here, right now.
LEARN MORE
WE’RE HIRING
"Improving human health requires brave thinkers who are willing to explore new ideas and build on successes. Unleash your potential with us.
SEARCH JOBSArticle
Therapeutic Breakthroughs Drive Dealmaking in Endocrine and Metabolic Disorders
IQVIA Pharma Deals
Dec 18, 2023
Endocrine and metabolic diseases have increasingly become more prominent in dealmaking within the life sciences sector, as high prevalence of the diseases combined with the significant unmet medical need has piqued the interest of innovators.Notably, there has been a marked increase in endocrine/metabolic deal volume from 2022 to 2023, with drug candidates targeting obesity, diabetes and rare metabolic disorders being the key drivers of several high-profile deals, particularly in relation to novel therapeutic modalities and delivery approaches.
Despite significant advances within the field in recent years, there continues to be an unmet medical need for patients living with endocrine and metabolic disorders. This article will discuss life science deals that have been primarily driven by endocrine, metabolic and nutritional disease indications as defined by WHO ICD-10 code and sourced from the IQVIA Pharma Deals platform. Endocrine and etabolic deals have seen an uptick in recent years and now represent 8% of all publicly disclosed deals in Pharma Deals, compared to oncology which is the leading dealmaking therapeutic area and comprises over 20% of all deals. So far in 2023, biopharma companies have committed up to $12.3 billion in M&A deals and up to $12.5 billion in potential aggregate total deal value on alliances focused on endocrine/metabolic assets, as they look to invest in the growing market.
Technological advances have unveiled new drug targets and mechanisms of action which have led to several endocrine/metabolic assets successfully reaching the clinic as well as a number of notable regulatory breakthroughs for the field. For example, glucagon-like peptide-1 (GLP-1) receptor agonists have drawn significant attention in recent months due to their transformative potential to treat both diabetes and obesity.
To read more, fill in your details on the left to download the article.
Despite significant advances within the field in recent years, there continues to be an unmet medical need for patients living with endocrine and metabolic disorders. This article will discuss life science deals that have been primarily driven by endocrine, metabolic and nutritional disease indications as defined by WHO ICD-10 code and sourced from the IQVIA Pharma Deals platform. Endocrine and etabolic deals have seen an uptick in recent years and now represent 8% of all publicly disclosed deals in Pharma Deals, compared to oncology which is the leading dealmaking therapeutic area and comprises over 20% of all deals. So far in 2023, biopharma companies have committed up to $12.3 billion in M&A deals and up to $12.5 billion in potential aggregate total deal value on alliances focused on endocrine/metabolic assets, as they look to invest in the growing market.
Technological advances have unveiled new drug targets and mechanisms of action which have led to several endocrine/metabolic assets successfully reaching the clinic as well as a number of notable regulatory breakthroughs for the field. For example, glucagon-like peptide-1 (GLP-1) receptor agonists have drawn significant attention in recent months due to their transformative potential to treat both diabetes and obesity.
To read more, fill in your details on the left to download the article.